WASHINGTON — Drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine in an effort to expand supply more quickly, a Biden administration official confirmed Tuesday.

The announcement comes as the White House looks to speed the production of the single-dose vaccine. Officials have said J&J faced unexpected production issues with its vaccine and produced only 3.9 million doses ahead of its receiving emergency use authorization on Saturday. The company says it is on pace to deliver 100 million doses by the end of June.

The assistance from Merck was expected to help J&J meet its production commitments and expand supply even further, but the administration did not immediately provide specifics.

President Joe Biden is set to highlight the development in a speech Tuesday afternoon. The official confirmed Merck's involvement on condition of anonymity ahead of Biden's public announcement.

The news was first reported by The Washington Post.

Merck is headquartered in Kenilworth and Johnson & Johnson is based in New Brunswick.

(Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

LOOK: Answers to 30 common COVID-19 vaccine questions

While much is still unknown about the coronavirus and the future, what is known is that the currently available vaccines have gone through all three trial phases and are safe and effective. It will be necessary for as many Americans as possible to be vaccinated in order to finally return to some level of pre-pandemic normalcy, and hopefully these 30 answers provided here will help readers get vaccinated as soon they are able.

The 6 best ice cream places in NJ

COMPARE: Highest 2020 property taxes in each county

More From New Jersey 101.5 FM